Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Staff editor

06.05.2021

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Watch our interview with Matthew Henn, Executive Vice President and Chief Scientific Officer of Seres Therapeutics.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Via Podgora 12/A, 20122, Milan, Italy – VAT: IT05299040963

This communication is only intended for business-to-business and health care professionals.
This communication is not intended for consumers of final consumer goods.
Nothing on this page is meant to be perceived as an approved claim.

Matthew Henn (Seres Therapeutics): ‘Microbiome research will have a large impact on human health’

Latest related content

Gut bacteria and metabolites may be drivers of chronic pain in sickle cell disease

Maternal microbes may trigger preterm birth by altering pregnancy hormones

Standardizing evidence on probiotics in acute gastroenteritis: why guidelines diverge and clinicians are confused

Gut-brain connection may be a predictor of Alzheimer’s and Parkinson’s risk

New study shows how specific gut bacteria evolve and adapt across animal species

Bio-inspired capsule offers a non-invasive way to sample hidden microbes in the gut

Latest News